血清CD44v6表达在结直肠癌中的临床应用价值

目的 探讨血清可溶性细胞表面黏附分子sCD44v6在结、直肠癌中的临床应用价值.方法 96例不同Duke分期结、直肠癌患者和24例健康者,分别采用酶联免疫吸附法(ELISA)定量检测其血清sCD44v浓度,化学发光免疫法检测血清CEA浓度;并结合临床资料进行分析.结果 结、直肠癌患者sCD44v6浓度为275.3±115.8 ng/ml,明显高于健康对照组(61.3±7.8 ng/ml)(P＜0.05),若以健康对照组的(-x)+2s(76.9 ng/ml)作为正常上限值,其阳性率为73.96%;sCD44v6水平随癌肿Duke分期的升级和肿瘤细胞的转移而呈现递增趋势,各组之间比较差异有统计学意义(P＜0.05).与CEA相比,sCD44v6水平在反映癌组织浸润和转移程度上更直接、敏感.结论 结、直肠癌患者sCD44v6水平和阳性率均显著增高,并与肿瘤的分期和扩散转移程度密切相关;术前sCD44v6水平检测可作为结、直肠癌患者病程和转移预测的一个重要指标.

The Clinical value of detecting CD44v6 in plasma for colon and rectum cancer

Objective To explore the clinical value of measuring solubie serum CD44 variant 6sCD44v6 in patients with colorectal cancer. Methods Serum leves of sCD44v6 and CEA in96 patients with colorectal and in 24 healthy indivduals were detected by ELISA andchem-iluninesenle immunoassoly,respectively.Some ehnieal pathological indexes were analyzed.Results Mean sCD44v6 level in patients with colorectal cancer was 275.3+-115.8 ng/ml,which was significantly hirher than that in healthy controls(61.3+-7.8 ng/ml,P＜0.05).When using the mean+2s sCD44v6 level of healthy controls as the cut-off value,sCD44v6 level were abnormally elevated in 71 of 96(73.96%)patients with coloreeatal cancer.Conclusion The sCD44v6 leveland positive rate also increased with Dukesstage and tumor metastasis Compared with serum CEA level,the sCD44v6 level might reflect the tumor invasion and metastasis more directly and sensitively.